Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Kura Oncology, Inc. | kura-10k_20171231.htm |
| EX-32.1 - EX-32.1 - Kura Oncology, Inc. | kura-ex321_6.htm |
| EX-31.2 - EX-31.2 - Kura Oncology, Inc. | kura-ex312_10.htm |
| EX-31.1 - EX-31.1 - Kura Oncology, Inc. | kura-ex311_12.htm |
| EX-10.24 - EX-10.24 - Kura Oncology, Inc. | kura-ex1024_450.htm |
| EX-10.23 - EX-10.23 - Kura Oncology, Inc. | kura-ex1023_180.htm |
| EX-10.10 - EX-10.10 - Kura Oncology, Inc. | kura-ex1010_616.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statement (Form S-3 Nos. 333-210614 and 333-221479) of Kura Oncology, Inc., and |
|
|
2. |
Registration Statement (Form S-8 Nos. 333-210260 and 333-216683) pertaining to the Amended and Restated 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan of Kura Oncology, Inc.; |
of our report dated March 12, 2018, with respect to the financial statements of Kura Oncology, Inc., included in this Annual Report (Form 10-K) of Kura Oncology, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
San Diego, California
March 12, 2018